Orchard Therapeutics shares are trading higher after the company agreed to be acquired by Japan's Kyowa Kirin for $16.00 per ADS in cash plus an additional contingent value right of $1.00 per ADS.
Portfolio Pulse from Benzinga Newsdesk
Orchard Therapeutics has agreed to be acquired by Japan's Kyowa Kirin for $16.00 per ADS in cash, with an additional contingent value right of $1.00 per ADS. This has led to a rise in Orchard Therapeutics' share price.
October 05, 2023 | 10:19 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Orchard Therapeutics' shares are trading higher after the company agreed to be acquired by Kyowa Kirin. The acquisition price is $16.00 per ADS in cash plus an additional contingent value right of $1.00 per ADS.
The acquisition agreement has led to a rise in Orchard Therapeutics' share price. The acquisition price of $16.00 per ADS in cash plus an additional contingent value right of $1.00 per ADS is a positive development for the company and its shareholders, leading to the increase in share price.
CONFIDENCE 100
IMPORTANCE 100
RELEVANCE 100